Livmoniplimab (ABBV-151)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Livmoniplimab (ABBV-151), covering 2025-05-25 to 2025-05-25. Get the full timeline:
Most recent: Clinical Trial Update: Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors [Phase 1]